Heloise Bhatt
PhD
Immunology Researcher
👥Biography 个人简介
Heloise Bhatt has contributed to the biology of LAG-3 (Lymphocyte Activation Gene-3) — a second-generation immune checkpoint whose blockade has now been validated in combination with anti-PD-1. The RELATIVITY-047 trial established relatlimab (anti-LAG-3) plus nivolumab as a superior first-line melanoma treatment compared to nivolumab alone, marking the first approval of a combination checkpoint blockade regimen beyond ipilimumab-nivolumab.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Heloise Bhatt 的研究动态
Follow Heloise Bhatt's research updates
留下邮箱，当我们发布与 Heloise Bhatt（Bristol Myers Squibb）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment